Previous 10 | Next 10 |
Calliditas Therapeutics AB (CALT) has announced that the company has terminated the previously announced proposed global offering due to deterioration in market conditions."Calliditas is well capitalized with a cash runway into Q3 of 2022 and we believe there are financing options which ...
Calliditas announces termination of the proposed global offering PR Newswire STOCKHOLM , Jan. 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; Nasdaq - CALT) today announced that despite significant interest, it wil...
Calliditas Therapeutics ([[CALT]] -10.3%) launched a proposed public offering of American Depositary Shares (representing two common shares), in the U.S. for trading on Nasdaq Global Select Market and a concurrent private placement of common shares (global offering).Size of the glob...
Calliditas Therapeutics launches proposed global offering PR Newswire STOCKHOLM , Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depo...
Calliditas Therapeutics ([[CALT]]) has announced that all 360 patients have been enrolled for the global Phase 3 trial NefIgArd comprising Part A and Part B, evaluating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN).Calliditas read out topline data from P...
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial PR Newswire STOCKHOLM , Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enro...
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day...
Calliditas Therapeutics' ([[CALT]] +6.4%) subsidiary Genkyotex has announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.The study in 46 healthy volunteers demonstrated that setanaxib is well tolerated ...
Positive Phase 1 results in high-dose setanaxib trial PR Newswire STOCKHOLM , Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data...
Agenda for Calliditas virtual R&D Day on January 20, 2021 Agenda for Calliditas virtual R&D Day on January 20, 2021 PR Newswire STOCKHOLM , Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...